

PROVINCIAL FUNDING SUMMARY

Ibrutinib (Imbruvica) for Mantle Cell Lymphoma (relapsed/refractory) (pCODR 10073)

pERC Recommendation: Recommends

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: August 4, 2016

This information is current as of December 3, 2018.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Mar 1, 2018	Relapsed or refractory mantle-cell lymphoma <ul style="list-style-type: none"> • AST/ALT less than 3 x ULN • A Compassionate Access Program (CAP) approval is required prior to the initiation of treatment
AB	Funded	May 8, 2018	For the treatment of patients with relapsed or refractory mantle cell lymphoma. Treatment should be for patients with a good performance status and until disease progression or unacceptable toxicity.
SK	Funded	Oct 1, 2017	For the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL).
MB	Funded	Oct 19, 2017	For the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL).
ON	Funded	Oct 1, 2017	Initial criteria: For patients with relapsed or refractory mantle cell lymphoma who have received at least one prior therapy. Renewal criteria: Patient has experienced no disease progression while on Imbruvica therapy.
NS	Funded	Oct 15, 2018	As a single agent treatment option for patients with relapsed or refractory mantle cell lymphoma who have received at least one prior therapy. Patients should have a good performance status. Treatment should be discontinued upon disease progression or unacceptable toxicity.
NB	Funded	June 11, 2018	For the treatment of patients with relapsed or refractory mantle cell lymphoma. Patients must have a good performance status. Treatment should be discontinued upon disease progression or unacceptable toxicity.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
NL	Funded	May 1, 2018	For the treatment of patients with relapsed / refractory mantle cell lymphoma (MCL).
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.